Blog

Spurred by Abiomed deal, J&J medtech business grows in 2023

Despite Abiomed’s recent troubles with the U.S. Food and Drug Administration, including a partial recall and warning letter from the agency, the Danvers medical device firm boosted Johnson & Johnson’s medtech business one year after being acquired by the pharma giant.

Read More